Trajenta gets expanded EU indication
This article was originally published in Scrip
Executive Summary
The EMA has now approved an expanded use for Boehringer Ingelheim/Lilly’s DPP-IV inhibitor Trajenta (linagliptin) for use in type 2 diabetes following a positive recommendation by the CHMP in September.